The Oncologic Drugs Advisory Committee has voted against a recommendation for the U.S. Food and Drug Administration to approve panobinostat, a drug created by Novartis for the treatment of multiple myeloma.

READ FULL ARTICLE Curated publisher From www.thepharmaletter.com